Form 4: Altimmune Director Wayne Pisano Receives Stock Options
Statement of Changes in Beneficial Ownership
Director Wayne Pisano was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.
Summary
- Director Wayne Pisano received a grant of 48,800 stock options on May 1, 2026.
- The options have an exercise price of $2.82 per share.
- The options are set to expire on May 1, 2036.
- Vesting occurs in substantially equal monthly installments over a 12-month period following the grant date.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Granting of stock options results in potential future dilution for existing shareholders.
Risks
- The value of the options is dependent on the future market performance of Altimmune common stock.
- Vesting is contingent upon the director's continued service to the company.
Future Outlook
The options vest over a 12-month period, indicating a commitment to the company's governance and oversight through May 2027.
Management Comments
- The options were granted pursuant to the Company's non-employee director compensation policy.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain experienced board members while aligning incentives with corporate performance.
Comparison to Industry Standards
- The use of monthly vesting over one year is a standard retention mechanism for board members in mid-cap biotech firms.
- The grant size is consistent with typical compensation packages for directors in similar-stage clinical development companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 48,800 stock options to Director Wayne Pisano. | 05/01/2026 | Standard alignment of director compensation with company performance. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of options in monthly installments through May 1, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/01/2026 | Grant date of stock options and date of earliest transaction. |
| 05/01/2036 | Expiration date of the granted stock options. |
Keywords
Altimmune, ALT, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.